Alivus Life Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 26 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹16.6K Cr

The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.

From Alivus Life's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.

Price

₹1,348

Market Cap

₹16.6K Cr

P/E Ratio

26.7

How does Alivus Life rank in Pharmaceuticals & Biotechnology?

Compare Alivus Life against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Alivus Life — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half.
→Non-GPL business grew by ~40% driven by successful new product launches; outlook remains strong.
→Anticipated rebound in GPL business in the second half of FY '26.
→CDMO segment expected to show a meaningful turnaround in H2 FY '26 with five projects ramping up.
→Japan market to see new commercial launches, with 8-9 products going commercial, up from 4 previously, expecting 4 new molecules launched annually.
→Broad-based growth expected from emerging markets, LATAM, Japan, Europe, and India.
→Overall capex and capacity expansions (Solapur, Ankleshwar, Dahej) on track to support growth.
→Guidance reaffirmed for high single-digit revenue growth in FY '26.

📈 Profitability & Margins

→Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.
→High single-digit revenue growth is reaffirmed for FY '26, fueled by broad-based external sales growth, turnaround in GPL business, and ramp-up of CDMO projects.
→CDMO business is anticipated to rebound in the second half with new projects and existing project ramp-up.
→Profitability expected to sustain margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiencies.
→EBITDA and PAT margins showed significant year-on-year improvement, indicating profitability momentum.
→Working capital stable, with receivable days around 148 days, limited scope to significantly reduce working capital days.
→Capex spend reduced in H1 but projects remain on track to support growth.
→Pipeline strong with 586 DMF/CEP filings and 26 high-potent APIs under development.

See what Alivus Life said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.
→Board-approved capex budget for FY '26 is INR600 crores, including INR190 crores carryover from FY '25.
→Capex slowed in H1; R&D center spend is half the planned INR90-100 crores for FY '26, causing some delay.
→Planned capex spend for H2 FY '26 is around INR250 crores.
→Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing well and on track.
→Ankleshwar projects to be operational by June 2026 (Q2 FY '27).
→Dahej projects expected operational from Q1 FY '27.
→Solapur facility targeted to start from April next year.
→Strategic focus on own R&D center with expandable space to support growth for next 5 years.
→Company holds INR650+ crores in cash; evaluating inorganic and other capital deployment opportunities but currently prioritizing organic growth.

💰 Fundraising & Capital Structure

→The transcript does not mention any current or planned fundraising through debt or equity.
→Alivus Life Sciences Limited remains a net debt-free company as of September 30, 2025.
→The company has cash and cash equivalents, including short-term investments, amounting to INR 653 crores.
→They have more than INR 650 crores of cash on hand and prefer to reinvest this cash back into the business for growth and capex needs.
→Capex projects are funded through internal accruals and better credit from suppliers, avoiding the need for external debt or equity raising at this time.
→The company is evaluating capital deployment opportunities but no specific plans for raising debt or equity were disclosed for the near term.

See what Alivus Life said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for Alivus Life Sciences Limited. However, some related insights are: - The CDMO business has a healthy pipeline with 586 DMF and CEP filings globally as of September 30, 2025. - There are 26 high-potent API products in the active development grid, representing a $66 billion addressable market. - The company is confident of a meaningful turnaround in the CDMO segment in H2 FY '26 due to new projects and ramp-up of existing projects. - The outlook for GPL business is positive with expected improvement in the second half of FY '26. - New product launches and a strong pipeline are driving growth expectations. - Capacities at Solapur, Ankleshwar, and Dahej are expanding to support business growth. No direct figures or detailed order backlog values are disclosed in the transcript.

Key Metrics

How does Alivus Life rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alivus Life

See full Pharmaceuticals & Biotechnology sector rankings

What ALIVUS's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

SOLARA (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
SUNPHARMA (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
ZYDUSLIFE (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
SUDEEPPHRM (Q2 FY26)
NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area. Key concall takeaways…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Alivus Life Q2 FY26 results?

What is Alivus Life share price analysis?

Alivus Life currently shows a neutral. The stock trades at a P/E of 26.7 with a market cap of ₹16,585 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alivus Life planning capital expenditure?

Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.

Keep Alivus Life on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.